To evaluate if the ‘switched’ mCherry+ cells retain the same properties, we immunostained the primary and regressed tamoxifen-treated melanoma tissue sections with mCherry and Mitfa antibodies (Fig. 5F,G). This evidence concerns the gene MITF and melanoma.